Under certain clinical circumstances,
folic acid can have undesirable effects. We investigated the following: (i) the effects of moderately high
folic acid supplementation on the course of liver impairment in CCl(4)-treated rats and (ii) the influence of
folic acid supplements on the hepatic recovery following the interruption of the CCl(4)-induced toxic injury. Four experimental groups of rats were used: CCl(4)-treated rats (0.5 ml of CCl(4) twice a week i.p.) fed standard chow for up to 12 weeks (Group A); treated rats fed chow supplemented with 25 mg/kg
folic acid from weeks 6 to 12 (Group B); treated rats fed a standard diet but with CCl(4) discontinued after 6 weeks to allow for tissue recovery over 4 weeks (Group C); rats as Group C but fed a diet supplemented with 25 mg/kg
folic acid from weeks 6 to 10 (Group D). Liver and blood samples were obtained for biochemical, histological, and gene expression analyses. Animals that received the supplement had a higher content of
collagen, activated stellate cells, and apoptotic parenchymal cells in biopsy tissue at weeks 8 and 10 of treatment and more extensive alterations in
serum albumin and
bilirubin concentrations (Group B vs. Group A). In some of the time periods analyzed, alterations were observed in the expression of genes related to apoptosis (
B-cell leukemia/
lymphoma 2, inhibitor of apoptosis 2) and to
fibrosis (
procollagen I,
matrix metalloproteinase 7). In the recovery period (Groups C and D),
folic acid administration was associated with increased hepatic
inflammation and apoptosis and with a decrease in the
tissue inhibitor of metalloproteinase-3 expression following 1 week of recovery. We conclude that
folic acid administration aggravates the development of
fibrosis in CCl(4)-treated rats. Follow-up studies are needed to determine whether
folic acid treatment would be contraindicated in patients with chronic
liver diseases.